(S)-N-(4-cyanobenzyl)pyrrolidine-2-carboxamide hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-N-(4-cyanobenzyl)pyrrolidine-2-carboxamide hydrochloride
• 英文别名: (2S)-N-[(4-cyanophenyl)methyl]pyrrolidine-2-carboxamide;hydrochloride
• 化学式: C₁₃H₁₅N₃O*ClH
• 分子量: 265.743
• InChiKey: MHNFTWYKHQQPFD-YDALLXLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.35
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  64.9
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-N-(4-cyanobenzyl)pyrrolidine-2-carboxamide hydrochloride 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸羟胺 、 乙酸酐 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 47.5h， 生成 tert-butyl ((R)-1-((S)-2-((4-carbamimidoylbenzyl)carbamoyl)pyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl)carbamate
  参考文献：
  名称：

  Binding cooperativity between a ligand carbonyl group and a hydrophobic side chain can be enhanced by additional H-bonds in a distance dependent manner: A case study with thrombin inhibitors

  摘要：

  One of the underappreciated non-covalent binding factors, which can significantly affect ligand-protein binding affinity, is the cooperativity between ligand functional groups. Using four different series of thrombin inhibitors, we reveal a strong positive cooperativity between an H-bond accepting carbonyl functionality and the adjacent P3 hydrophobic side chain. Adding an H-bond donating amine adjacent to the P3 hydrophobic side chain further increases this positive cooperativity thereby improving the Ki by as much as 546-fold. In contrast, adding an amidine multiple H-bond/salt bridge group in the distal S1 pocket does not affect this cooperativity. An analysis of the crystallographic B-factors of the ligand groups inside the binding site indicates that the strong cooperativity is mainly due to a significant mutual reduction in the residual mobility of the hydrophobic side chain and the H-bonding functionalities that is absent when the separation distance is large. This type of cooperativity is important to encode in binding affinity prediction software, and to consider in SAR studies. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.03.059
• 作为产物：
  描述：

  4-(氨甲基)苯腈盐酸盐 在 盐酸 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 19.0h， 生成 (S)-N-(4-cyanobenzyl)pyrrolidine-2-carboxamide hydrochloride
  参考文献：
  名称：

  Binding cooperativity between a ligand carbonyl group and a hydrophobic side chain can be enhanced by additional H-bonds in a distance dependent manner: A case study with thrombin inhibitors

  摘要：

  One of the underappreciated non-covalent binding factors, which can significantly affect ligand-protein binding affinity, is the cooperativity between ligand functional groups. Using four different series of thrombin inhibitors, we reveal a strong positive cooperativity between an H-bond accepting carbonyl functionality and the adjacent P3 hydrophobic side chain. Adding an H-bond donating amine adjacent to the P3 hydrophobic side chain further increases this positive cooperativity thereby improving the Ki by as much as 546-fold. In contrast, adding an amidine multiple H-bond/salt bridge group in the distal S1 pocket does not affect this cooperativity. An analysis of the crystallographic B-factors of the ligand groups inside the binding site indicates that the strong cooperativity is mainly due to a significant mutual reduction in the residual mobility of the hydrophobic side chain and the H-bonding functionalities that is absent when the separation distance is large. This type of cooperativity is important to encode in binding affinity prediction software, and to consider in SAR studies. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.03.059

文献信息

• [EN] PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS<br/>[FR] PYRROLOPYRIMIDINE AMINES EN TANT QU'INHIBITEURS DU COMPLÉMENT
  申请人：BIOCRYST PHARM INC

  公开号：WO2021202977A1

  公开（公告）日：2021-10-07

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  本文披露了式（I）的化合物及其药用盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活动特征的疾病或状况的方法。
• PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF
  申请人：Li Min

  公开号：US20130296245A1

  公开（公告）日：2013-11-07

  Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases.

  提供了一种化合物的公式(I)，其药用盐，制备方法以及用于抑制凝血酶的应用，以及在治疗和预防凝血酶介导和相关疾病中的应用。
• Ligand binding cooperativity: Bioisosteric replacement of CO with SO2 among thrombin inhibitors
  作者：Ahmed M. Said、David G. Hangauer

  DOI：10.1016/j.bmcl.2016.07.024

  日期：2016.8

  Ligand–protein binding is a complex process that involves the formation of number of non-covalent interactions, e.g. H-bonds and hydrophobic interactions, between the ligand and the protein host. Upon binding, ligand functional groups can act synergistically (positive cooperativity) to improve the overall ligand binding affinity beyond what would be expected from their individual contributions. In

  配体与蛋白质的结合是一个复杂的过程，涉及在配体与蛋白质宿主之间形成许多非共价相互作用，例如H键和疏水相互作用。结合后，配体官能团可以协同作用（正协同作用），以提高总体配体结合亲和力，超出其各自贡献的预期范围。在这项研究中，使用凝血酶作为蛋白质模型系统，我们评估了用磺酰基官能团生物等位取代羰基官能团对其与凝血酶的H键之间的正协同作用以及相邻S3口袋中的疏水结合的影响。当用磺酰基取代羰基时，观察到的正协同性大大降低。
• Novel thrombin inhibitors
  申请人：——

  公开号：US20020169318A1

  公开（公告）日：2002-11-14

  The invention relates to a compound of the formula I 1 or a salt thereof with a physiologically tolerated acid, or stereoisomers thereof, wherein R 1 , R 2 , A, B, C and D have the meanings described in the specification.

  本发明涉及一种公式I1的化合物或其生理上耐受的酸盐，或其立体异构体，其中R1，R2，A，B，C和D的含义如说明书中所述。
• Novel thrombin inhibitors, the preparation and use thereof
  申请人：Boehm Hans-Joachim

  公开号：US20060111553A1

  公开（公告）日：2006-05-25

  Compounds of the formula and the salts thereof with physiologically tolerated acids and the stereoisomers thereof, in which the substituents have the meanings stated in the description, are described. Also disclosed are intermediates for their preparation. The compounds are suitable for controlling diseases.

  本文描述了化学式及其生理耐受酸盐和立体异构体，其中取代基具有所述描述中的含义。还公开了其制备中间体。这些化合物适用于控制疾病。